These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 33839254)
21. Mesalazine-probiotics beads for acetic acid experimental colitis: formulation and characterization of a promising new therapeutic strategy for ulcerative colitis. Vishwakarma N; Ganeshpurkar A; Pandey V; Dubey N; Bansal D Drug Deliv; 2015 Jan; 22(1):94-9. PubMed ID: 24491122 [TBL] [Abstract][Full Text] [Related]
22. Effect of nimesulide on acetic acid- and leukotriene-induced inflammatory bowel disease in rats. Singh VP; Patil CS; Jain NK; Singh A; Kulkarni SK Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):163-75. PubMed ID: 14518559 [TBL] [Abstract][Full Text] [Related]
23. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Wallace JL; Vergnolle N; Muscará MN; Asfaha S; Chapman K; McKnight W; Del Soldato P; Morelli A; Fiorucci S Gastroenterology; 1999 Sep; 117(3):557-66. PubMed ID: 10464131 [TBL] [Abstract][Full Text] [Related]
24. Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach. Suneela D; Gaurav V; Himanshu R Inflamm Allergy Drug Targets; 2013 Oct; 12(5):328-40. PubMed ID: 24001333 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles. Aggarwal R; Kumar S; Kaushik P; Kaushik D; Gupta GK Eur J Med Chem; 2013 Apr; 62():508-14. PubMed ID: 23416192 [TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of pyridine-linked indanone derivatives: Potential agents for inflammatory bowel disease. Kadayat TM; Banskota S; Bist G; Gurung P; Magar TBT; Shrestha A; Kim JA; Lee ES Bioorg Med Chem Lett; 2018 Aug; 28(14):2436-2441. PubMed ID: 29910080 [TBL] [Abstract][Full Text] [Related]
27. Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (Vaccinium corymbosum L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model. Pereira SR; Pereira R; Figueiredo I; Freitas V; Dinis TC; Almeida LM PLoS One; 2017; 12(3):e0174116. PubMed ID: 28329021 [TBL] [Abstract][Full Text] [Related]
28. Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis. Duan H; Lü S; Qin H; Gao C; Bai X; Wei Y; Wu X; Liu M; Zhang X; Liu Z Int J Pharm; 2017 Jan; 516(1-2):214-224. PubMed ID: 27851980 [TBL] [Abstract][Full Text] [Related]
29. An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. Carbo A; Gandour RD; Hontecillas R; Philipson N; Uren A; Bassaganya-Riera J J Med Chem; 2016 Nov; 59(22):10113-10126. PubMed ID: 27933891 [TBL] [Abstract][Full Text] [Related]
30. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Horváth K; Varga C; Berkó A; Pósa A; László F; Whittle BJ Eur J Pharmacol; 2008 Mar; 581(3):315-23. PubMed ID: 18215658 [TBL] [Abstract][Full Text] [Related]
31. Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Subramanian S; Rhodes JM; Hart CA; Tam B; Roberts CL; Smith SL; Corkill JE; Winstanley C; Virji M; Campbell BJ Inflamm Bowel Dis; 2008 Feb; 14(2):162-75. PubMed ID: 17941093 [TBL] [Abstract][Full Text] [Related]
32. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action. Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725 [TBL] [Abstract][Full Text] [Related]
33. Pluronic lecithin organogel of 5-aminosalicylic acid for wound healing. Sanapalli BKR; Kannan E; Balasubramanian S; Natarajan J; Baruah UK; Karri VVSR Drug Dev Ind Pharm; 2018 Oct; 44(10):1650-1658. PubMed ID: 29848103 [TBL] [Abstract][Full Text] [Related]
34. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
35. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease. Stobaugh DJ; Deepak P Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311 [TBL] [Abstract][Full Text] [Related]
36. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Bonapace CR; Mays DA Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055 [TBL] [Abstract][Full Text] [Related]
37. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Dubuquoy L; Rousseaux C; Thuru X; Peyrin-Biroulet L; Romano O; Chavatte P; Chamaillard M; Desreumaux P Gut; 2006 Sep; 55(9):1341-9. PubMed ID: 16905700 [TBL] [Abstract][Full Text] [Related]
38. Antioxidant and intestinal anti-inflammatory effects of plant-derived coumarin derivatives. Witaicenis A; Seito LN; da Silveira Chagas A; de Almeida LD; Luchini AC; Rodrigues-Orsi P; Cestari SH; Di Stasi LC Phytomedicine; 2014 Feb; 21(3):240-6. PubMed ID: 24176844 [TBL] [Abstract][Full Text] [Related]
39. Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis. Ramadass SK; Perumal S; Jabaris SL; Madhan B Eur J Pharm Sci; 2013 Jan; 48(1-2):104-10. PubMed ID: 23137838 [TBL] [Abstract][Full Text] [Related]
40. Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors. Grover J; Kumar V; Sobhia ME; Jachak SM Bioorg Med Chem Lett; 2014 Oct; 24(19):4638-4642. PubMed ID: 25219899 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]